BioStock: Spago Nanomedical on the oversubscribed rights issue and the plan ahead
Recently, Spago Nanomedical announced the outcome of the completed rights issue aimed at investing in their cancer treatment project Tumorad. The high interest - the issue was oversubscribed by 52 per cent - prompted the company to take advantage of the overallotment issue of 10 MSEK. BioStock reached out to CEO Mats Hansen for a comment on the outcome and the plans for the company in the near term.
Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/